Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Golconda Gold Announces the Election of Paul Olmsted and James Colter Eadie to the Board of Directors
Standard Uranium Initiates 2026 Drill Program at the Davidson River Uranium Project, Southwest Athabasca Basin
Nuvau Minerals commences PEA study to advance Matagami restart strategy, which includes a fully permitted critical metals mine
